(a) HXR9 retards SK-OV3 tumour growth in mice. Mice were treated twice weekly with HXR9 (10 mg/Kg)iv, after an initial dose of 100 mg/Kg iv when the mean tumour volume reached 100 mm3. Error bars represent the SEM for each data point. * indicates a significant difference between treatment groups, p < 0.05 (Mann-Whitney test). (b) HXR9 accumulation in SK-OV3 tumours. Tumours were removed from mice at 4 hours, 12 hours and 24 hours after an initial dose of HXR9 at 100 mg/Kg iv and the amount of HXR9 in the tumour tissue was assessed using dot blotting with an anti-HXR9 antibody.